Morgan Stanley Aktie
WKN: 885836 / ISIN: US6174464486
29.09.2025 11:36:00
|
Morgan Stanley expects Novo Nordisk Alzheimer trial to fail as it slashes rating
Morgan Stanley analysts say a trial to test whether Novo Nordisk’s blockbuster weight-loss drug also will work against Alzheimer’s is likely to fail, as it set the most pessimistic target price forecast of any Wall Street bank on the Danish drugmaker.Weiter zum vollständigen Artikel bei MarketWatch

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Morgan Stanleymehr Nachrichten
Analysen zu Morgan Stanleymehr Analysen
16.07.24 | Morgan Stanley Neutral | UBS AG |
Aktien in diesem Artikel
Morgan Stanley | 136,90 | -0,22% |
|
Morgan Stanley Deposit Shs Repr 1-1000th Flt Rate Non Cum Pfd Shs Series - A- | 22,02 | -0,94% |
|
Morgan Stanley Deposit Shs Repr 1-1000th Non-Cum Pfd Registered Shs Series -K- | 25,04 | 0,28% |
|
Morgan Stanley Deposit Shs Repr 1-1000th Non-Cum Pfd Shs Series -E- | 25,83 | 0,31% |
|
Morgan Stanley Deposit Shs Repr 1-1000th Non-Cum Pfd Shs Series -I- | 25,43 | 0,24% |
|
Morgan Stanley Deposit Shs Repr 1-1000th Non-Cum Pfd Shs Series -F- | 25,62 | 0,39% |
|
Novo Nordisk | 46,37 | -2,06% |
|
Novo Nordisk (spons. ADRs) | 46,80 | -0,53% |
|
Trial Holdings Inc. Registered Shs | 2 415,00 | 1,64% |
|